Emmaus Life Sciences Files 8-K on Financials

TL;DR

Emmaus Life Sciences dropped an 8-K on financials, check it out.

AI Summary

Emmaus Life Sciences, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company was formerly known as MYnd Analytics, Inc., CNS RESPONSE, INC., and STRATIVATION, INC., with name changes occurring in 2015, 2007, and 2005 respectively.

Why It Matters

This filing provides an update on Emmaus Life Sciences' financial performance and operational status, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any immediate or significant risks.

Key Players & Entities

• Emmaus Life Sciences, Inc. (company) — Registrant
• August 14, 2025 (date) — Date of Report
• MYnd Analytics, Inc. (company) — Former Company Name
• CNS RESPONSE, INC. (company) — Former Company Name
• STRATIVATION, INC. (company) — Former Company Name

FAQ

Filing Documents

• ea0253040-8k_emmaus.htm (8-K) — 27KB
• ea025304001ex99-1_emmaus.htm (EX-99.1) — 43KB
• ex99-1_001.jpg (GRAPHIC) — 10KB
• 0001213900-25-076672.txt ( ) — 248KB
• emma-20250814.xsd (EX-101.SCH) — 3KB
• emma-20250814_lab.xml (EX-101.LAB) — 33KB
• emma-20250814_pre.xml (EX-101.PRE) — 22KB
• ea0253040-8k_emmaus_htm.xml (XML) — 3KB

02 Results of Operation and Financial

Item 2.02 Results of Operation and Financial Condition. On August 14, 2025, Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") issued a press release announcing our results of operations and financial condition as of and for the three months ended June 30, 2025, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference. The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits See the accompanying Index to Exhibits, which is incorporated herein by reference. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 14, 2025 Emmaus Life Sciences, Inc. By: /s/ WILLIS LEE Name: Willis Lee Title: Chairman and Chief Executive Officer 2 INDEX TO EXHIBITS Exhibit Number Description 99.1 August 14, 2025 press release 104 Cover Page Interactive Date File (embedded within Inline XBRL document) 3

View Full Filing

View this 8-K filing on SEC EDGAR